-
-
-
-
-
-
-
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Announces FDA Agreement to Amend Special Protocol Assessment for Trial of AXPAXLI
-
-
-
-
-
-
-
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c
-
-
-
-
-
-
-
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
-
-
-
-
-
-
-
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Q2 Preliminary Net Product Revenue Surges 600% to $11.7M
-
976,210 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All